Fintech PR
Acoustic Wells wins 2019 MIT $100K Entrepreneurship Competition
Reading Time: 4 minutes
Acoustic Wells, a startup born in a laboratory at MIT that has created a new internet of things (IoT) control solution for oil wells that optimizes production while drastically reducing methane emissions, beat out seven finalists to win the Robert P. Goldberg $100,000 grand prize at last night’s MIT $100KEntrepreneurship Launch Finale held on the MIT campus.
Now in its 30th year, the MIT $100K Entrepreneurship Competition is an economic barometer for sectors of innovation that are receiving funding by venture capitalists. To date, the MIT $100K has facilitated the birth of more than 160 companies, which have gone on to raise $1.3 billion in venture capital and build $16 billion in market capitalization. More than 30 MIT $100K startups have been acquired by major companies, such as Oracle, Cisco, 3M, and Merck. Over 4,600 people are currently employed by MIT $100K companies. Recent IPOs include Akamai (AKAM) and Hubspot (HUBS).
A major challenge in the operation of oil and gas wells is the ability to monitor the operating conditions and health of pumping equipment without the need for prohibitively expensive equipment or daily inspections. To address this issue, Acoustic Wells has developed a patent-pending, acoustic-based control method that is capable of determining precisely down-hole conditions using a simple and affordable surface sensor. Acoustic Wells’ simple plug-and-play hardware processes the data at the edge and seamlessly connects to their cloud platform using long range IoT networks. Artificial intelligence algorithms automatically monitor the pump operation and optimize the production by adjusting the pumping rate while also predicting potential critical failures of the system.
Acoustic Wells’ founding team members are:
Dr. Sebastien Mannai, CEO, MIT PhD 2018 in Aerospace Engineering. He is currently engaged in postdoctoral work on AI signal processing in the Gas Turbine Laboratory of the Aerospace Department at MIT.
Dr. Charles-Henri Clerget, COO, who is currently engaged in postdoctoral work in the Earth Resources Laboratory with the Mathematics Department at MIT where he focuses on the big data analysis of drilling operations.
Louis Creteur, CTO and an industrial automation solution specialist who currently serves as IoT and Cloud Architect at Leanbox.
“We bring cutting edge technology in a simple package to help every oil and gas producer optimize their assets while reducing their emissions,” says Dr. Mannai.
A panel of judges chose Acoustic Wells based on value creation, value capture, and technological differentiation. Judges included: TJ Parker, Co-Founder & CEO, PillPack; Mira Wilczek, President & CEO, Cogo Labs; Thomas Collet, President, CEO & Director, Phrixus Pharmaceuticals; Tanguy Chau, Venture Investor; and Katie Rae, CEO & Managing Partner, The Engine.
A $10,000 Audience Choice Award was presented to The Read Read, one of the finalist teams. The Read Read has created a patent pending physical device that allows blind and low-vision children to independently learn phonics and braille, and gain early literacy to keep pace with their sighted peers. Users simply touch the braille and large-print letter manipulatives, and get immediate audio feedback. It was developed at the Harvard Innovations Lab, and piloted at the Perkins School for the Blind and the Harvard Graduate School of Education.
Six additional finalists included:
AgroBeads® are biodegradable spheres made from natural ingredients that hydrate plants according to their needs and support their growth and healthy development. Plants not only grow, but they do it faster, and healthier. AgroBeads® does not pollute the environment, improves the chances of germination, and contributes to the development of technologies that impact public health.
Mechanodontics is a new method that can be used instead of braces or aligners that moves teeth independently. Placed behind teeth so they cannot be seen, this method considerably shortens treatment time, allows for easier cleaning than traditional braces, and is more comfortable. This technology, which employs state-of-the-art simulations, allows orthodontists to apply the optimal amount of force to each tooth, easily fixing even complicated mal-alignments that are not correctable with aligners.
Myco Diagnostics is creating low-cost, robust medical diagnostics, using thermostable binding proteins to capture disease biomarkers from patient samples. They are producing point-of-care assays for the detection of urine-based biomarkers of tuberculosis, allowing them to address patient groups ill-served by traditional TB tests.
Posh offers a bot-creation platform using patent-pending technology that makes it easy to tailor a custom chatbot to meet companies’ needs. Not only can Posh answer company FAQs, but it can also help a company’s customers manage their accounts and convert prospects into sales. Posh does this while interacting with customers via the channels they prefer: across text, voice, social media and the web.
Qtech The team’s MIT-educated scientists have invented 3D Nano structured air filters that provide 20x filtration performance, 10x lifetime, and are recyclable at an estimated similar cost of a traditional HEPA filter. Filters catch not only flower pollens, but also bacteria and even viruses, and there is no need for replacements in years.
Stratagen Bio develops oxygen sensors to enable personalized cancer therapies, addressing the unmet clinical need of identifying low-oxygen treatment resistant tumors. They are enabling physicians to identify which cancer patients require a customized treatment to overcome resistance and improve outcomes and survival.
John Harthorne, a founder and former CEO of MassChallenge, served as the keynote speaker. Harthorne’s team, Robopsy, won the MIT $100K in 2007. He and Akhil Nigam went on to co-found MassChallenge, a not-for-profit, in 2010. Based on the MIT $100K model, their zero-equity startup accelerator has since gone global and has accelerated 1,975 startups that have raised more than $4.3 billion in funding, generated more than $2.5 billion in revenue, and created more than 121,000 total jobs. Harthorne now serves on MassChallenge’s Global Board of Directors.
Since its debut as the MIT $10K Entrepreneurship Competition in 1989, it has grown to include three independent contests – Pitch, Accelerate, and Launch – from September through May. Each contest focuses on developing specific founding skills. For each semi-finalist contender, the MIT $100K brings together a network of resources that includes mentorship from venture capitalists, serial entrepreneurs, corporate executives, and attorneys; media exposure; prototyping funds; business plan feedback; and discounted services. Altogether, almost $1M in non-dilutive prize money and other financial resources are awarded to help these new ventures accelerate. For more on the MIT $100K, please visit: www.mit100k.org
SOURCE MIT Sloan School of Management
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Fintech4 days agoHow to identify authenticity in crypto influencer channels
-
Latest News7 days ago
BMO Announces Election of Board of Directors
-
Latest News4 days ago
HSBC-backed fintech Monese is considering splitting its operations as it grapples with increasing losses.
-
Latest News3 days ago
EverBank has announced a groundbreaking partnership with Finzly, poised to revolutionize payment processing.
-
Latest News3 days ago
FinTech leaders express caution regarding the promises made in #Budget2024 concerning open banking, stating that the “devil is in the details.”
-
Latest News3 days ago
Gotion High-tech’s operating profit up 391% in 2023, nearly RMB 2.8 billion invested in R&D for the year
-
Latest News3 days ago
Aurionpro Solutions acquires Arya.ai, to power next generation Enterprise AI platforms for Financial Institutions
-
Latest News4 days ago
Wells Fargo, a leading financial institution, is set to revolutionize its trade finance operations by incorporating artificial intelligence (AI) technology through its collaboration with TradeSun.